Lucid Diagnostics Inc. (LUCD) Reports Q3 Loss, Lags Revenue Estimates

Core Insights - Lucid Diagnostics Inc. reported a quarterly loss of $0.1 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.06, marking an earnings surprise of -66.67% [1] - The company generated revenues of $1.21 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 6.85% and showing a slight increase from $1.17 million a year ago [2] - The stock has increased approximately 27% since the beginning of the year, outperforming the S&P 500's gain of 16.4% [3] Financial Performance - Over the last four quarters, Lucid Diagnostics has not surpassed consensus EPS estimates, with the current consensus EPS estimate for the upcoming quarter at -$0.07 and for the current fiscal year at -$0.35 [2][7] - The company has topped consensus revenue estimates only once in the last four quarters [2] Market Outlook - The earnings outlook and estimate revisions trend for Lucid Diagnostics were favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] - The Medical - Instruments industry, to which Lucid Diagnostics belongs, is currently in the top 29% of Zacks industries, suggesting a positive industry outlook [8]